Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Sotyktu™ (deucravacitinib) – New drug approval
September 9, 2022 - Bristol Myers Squibb announced the FDA approval of Sotyktu (deucravacitinib), for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
